Mersana Therapeutics has begun a Phase Ib extension study to evaluate its lead cancer product, XMT-1001, as a treatment for second-line gastric cancer and second-line and third-line non-small cell lung cancer.
The study will be conducted at ten clinical centres in the US.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The Phase Ib study follows the successful completion of a 74-patient Phase I clinical trial, which showed high and prolonged plasma levels of XMT-1001 active release products.
The study showed a safety profile free of the toxicities normally associated with topoisomerase I inhibitors, such as haemorrhagic cystitis and diarrhoea.
In addition, XMT-1001 demonstrated clinical activity, including tumour shrinkage and prolonged stable disease, in a heavily pre-treated patient population.
XMT-1001 is a novel DNA topoisomerase I inhibitor based on Mersana’s Fleximer polymer conjugate platform.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
